Statement of Advice

tapentadol (Palexia®) 50 mg film-coated tablets (No: 773/12)
Grunenthal Ltd

13 January 2012

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation 
tapentadol (Palexia®) is not recommended for use within NHS Scotland.

**Indication under review:** relief of moderate to severe acute pain in adults, which can be 
adequately managed only with opioid analgesics.

The holder of the marketing authorisation has not made a submission to SMC regarding 
this product in this indication. As a result we cannot recommend its use within 
NHSScotland.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to 
inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in 
Scotland in determining medicines for local use or local formulary inclusion. This advice 
does not override the individual responsibility of health professionals to make decisions in 
the exercise of their clinical judgement in the circumstances of the individual patient, in 
consultation with the patient and/or guardian or carer.*

Chairman, 
Scottish Medicines Consortium

Published 13 February, 2012